Peking University Pharmaceuticals announced that the company recently received the “Drug Registration Certificate” for rosuvastatin and ezetimib tablets approved by the State Drug Administration. The drug was approved for registration. The approval number is Sinopharm standard H20266204. The specification is that each tablet contains 10 mg of rosuvastatin calcium and 10 mg of ezetimib. It is mainly used for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.